Relapsing-remitting MS (RRMS) is the most common form of multiple sclerosis, accounting for roughly 85% of initial diagnoses. It follows a pattern of flare-ups, called relapses, where new neurological symptoms appear or existing ones worsen, followed by periods of partial or complete recovery. Understanding this cycle, what triggers it, and how it’s managed can make a real difference in how people navigate life with the condition.
How RRMS Affects the Nervous System
Multiple sclerosis is fundamentally a disease where the immune system turns against the central nervous system. In the classic understanding of RRMS, immune cells cross into the brain and spinal cord and attack myelin, the protective insulation around nerve fibers. This damage disrupts the electrical signals that nerves use to communicate, which is why symptoms can appear in almost any part of the body depending on where the damage occurs.
Each relapse represents a new wave of inflammation. When the inflammation subsides, the body can partially repair the damage or reroute signals around it, which is why symptoms often improve during remission. But the repair isn’t always complete. Over time, repeated attacks can leave behind scarring (the “sclerosis” in multiple sclerosis) and accumulated nerve damage that doesn’t fully heal. MRI studies show that progressive changes in the brain can happen even during periods when a person feels fine, meaning the disease can be quietly active between noticeable flare-ups.
What a Relapse Feels Like
A relapse brings new neurological symptoms or a clear worsening of old ones that lasts more than 24 hours. Most relapses last anywhere from a few days to several weeks, and some stretch into months. The specific symptoms depend entirely on which part of the nervous system is under attack.
In a large survey of people living with RRMS, the most commonly reported symptoms were:
- Fatigue (80% of respondents)
- Difficulty balancing or walking (73%)
- Numbness (64%)
- Pain (52%)
- Memory difficulties (52%)
- Muscle spasms (50%)
- Trouble concentrating (44%)
- Vision problems (43%)
- Urinary urgency or incontinence (41%)
- Depression (39%)
Less common but still notable symptoms include dizziness (34%), stiffness (37%), sexual dysfunction (27%), speech difficulty (25%), and tremor (15%). The range is wide, which is one reason MS is sometimes called a “snowflake disease.” No two people experience it the same way.
Relapses vs. Pseudo-Relapses
Not every flare-up of symptoms is a true relapse. Pseudo-relapses look and feel similar but aren’t driven by new inflammation in the nervous system. Instead, they’re triggered by outside factors like infection, physical or emotional stress, or heat exposure. A fever, for example, can temporarily worsen old MS symptoms because even a slight rise in body temperature slows nerve conduction in areas where myelin is already damaged.
The key difference: a true relapse reflects new immune activity and potential new damage, while a pseudo-relapse is temporary and resolves once the trigger is removed. Cooling down, treating an infection, or resting will typically ease a pseudo-relapse. Distinguishing between the two matters because treatment decisions depend on it, and an MS specialist can help sort this out through clinical evaluation and sometimes repeat MRI imaging.
How RRMS Is Diagnosed
Diagnosis relies on the McDonald criteria, most recently updated in 2017. The core requirement is demonstrating that damage has occurred in at least two separate areas of the central nervous system (called dissemination in space) at two different points in time (dissemination in time). This can be shown through a combination of clinical symptoms and MRI findings. Lesions in the brain’s cortex, the brainstem, and the spinal cord all count toward meeting these criteria.
In some cases, a spinal fluid test can speed up diagnosis. If a person has a single episode of neurological symptoms, known as a clinically isolated syndrome, and their spinal fluid contains specific immune markers called oligoclonal bands, that can be enough to confirm an MS diagnosis without waiting for a second clinical attack. The criteria also stress that no other condition better explains the symptoms, so the diagnostic process often involves ruling out infections, vitamin deficiencies, and other autoimmune conditions.
How Relapses Are Treated
When a relapse hits, the standard treatment is a short course of high-dose corticosteroids, typically taken over three to five days. These powerful anti-inflammatory medications work by tamping down the immune attack, which shortens the duration of the relapse and helps symptoms improve faster. They don’t change the long-term course of the disease, but they can make the difference between weeks of debilitating symptoms and a quicker return to baseline.
Corticosteroids can be given intravenously at a hospital or day clinic, or in some cases taken orally at home. Both routes are effective. Side effects during the short course can include insomnia, a metallic taste, mood changes, and increased appetite, but these resolve quickly once treatment ends.
Disease-Modifying Therapies
Beyond treating individual relapses, the bigger goal in RRMS management is reducing how often relapses happen and slowing the accumulation of disability. This is where disease-modifying therapies (DMTs) come in. These are long-term medications taken on an ongoing basis, not just during flare-ups.
DMTs are available in three forms: oral pills taken daily or twice daily, injectable medications given by self-injection on a set schedule, and infusion therapies administered at a clinic every few weeks to months. They range from moderate-efficacy options, which are often tried first and carry fewer risks, to high-efficacy treatments reserved for more aggressive disease. The choice depends on how active the disease is, how frequently relapses occur, and what a person is willing to tolerate in terms of side effects and monitoring requirements.
Starting a DMT early, ideally soon after diagnosis, is now the standard approach. The rationale is straightforward: the nerve damage that accumulates during relapses is easier to prevent than to reverse. People who begin treatment early tend to accumulate less disability over the following decades compared to those who delay.
Progression to Secondary Progressive MS
One of the most common concerns after an RRMS diagnosis is whether the disease will eventually shift to secondary progressive MS (SPMS). In SPMS, the pattern of distinct relapses and recoveries fades, replaced by a slow, steady worsening of neurological function.
This transition does happen for many people, but the timeline varies enormously. Studies estimate that the median time from first symptoms to SPMS conversion is around 19 years, though individual experiences range from as few as 1 to over 40 years. One study of Polish MS patients found an average conversion time of about 13 years. Women and men appear to transition at similar rates.
It’s worth noting that these statistics come largely from eras before modern DMTs were widely used. Today’s treatments are expected to delay or potentially prevent this transition for many people, though long-term data is still being gathered. The shift to SPMS is also not always obvious. It tends to be recognized in retrospect, when a neurologist notices that disability has been gradually worsening independent of relapses over a period of months or years.
Living With RRMS Between Relapses
Remission doesn’t always mean feeling completely normal. Many people with RRMS deal with persistent background symptoms even in their best periods. Fatigue is the most pervasive, affecting roughly 4 out of 5 people with the condition, and it’s a qualitatively different kind of tiredness than what healthy people experience. It can be disproportionate to activity level and resistant to rest.
Cognitive symptoms like difficulty concentrating and memory lapses affect nearly half of people with RRMS and can be among the most frustrating to manage because they’re invisible to others. Depression is also significantly more common in MS than in the general population, reported by about 39% of people with RRMS. This isn’t just a reaction to having a chronic illness. Inflammation in the brain itself contributes to mood changes.
Exercise, adequate sleep, stress management, and staying cool in hot environments all play a role in managing day-to-day symptoms and potentially reducing relapse frequency. These aren’t substitutes for DMTs, but they’re meaningful complements that improve quality of life in measurable ways.